Targeting Cancer using Curcumin Encapsulated Vesicular Drug Delivery Systems

Curr Pharm Des. 2021;27(1):2-14. doi: 10.2174/1381612826666200728151610.

Abstract

Curcumin is a major curcuminoid present in turmeric. The compound is attributed to various therapeutic properties, which include anti-oxidant, anti-inflammatory, anti-bacterial, anti-malarial, and neuroprotection. Due to its therapeutic potential, curcumin has been employed for centuries in treating different ailments. Curcumin has been investigated lately as a novel therapeutic agent in the treatment of cancer. However, the mechanisms by which curcumin exerts its cytotoxic effects on malignant cells are still not fully understood. One of the main limiting factors in the clinical use of curcumin is its poor bioavailability and rapid elimination. Advancements in drug delivery systems such as nanoparticle-based vesicular drug delivery platforms have improved several parameters, namely, drug bioavailability, solubility, stability, and controlled release properties. The use of curcumin-encapsulated niosomes to improve the physical and pharmacokinetic properties of curcumin is one such approach. This review provides an up-to-date summary of nanoparticle-based vesicular drug carriers and their therapeutic applications. Specifically, we focus on niosomes as novel drug delivery formulations and their potential in improving the delivery of challenging small molecules, including curcumin. Overall, the applications of such carriers will provide a new direction for novel pharmaceutical drug delivery, as well as for biotechnology, nutraceutical, and functional food industries.

Keywords: Cancer; curcumin; exosomes; liposomes; nanoformulations; niosomes; pro-niosomes; vesicular.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Curcumin* / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Liposomes / therapeutic use
  • Neoplasms* / drug therapy
  • Solubility

Substances

  • Liposomes
  • Curcumin